Antenolol: A Long-Acting Beta_1-Adrenoceptor Antagonist
Authors: ANDREW A. MCLEOD
Journal: Annals of Internal Medicine (1982)

Editorials1 February 1982Antenolol: A Long-Acting Beta1-Adrenoceptor AntagonistANDREW A. MCLEOD, M.B., M.R.C.P., DAVID G. SHAND, PH.D.ANDREW A. MCLEOD, M.B., M.R.C.P.Search for more papers by this author, DAVID G. SHAND, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-2-244 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAtenolol, a selective beta1-adrenoceptor antagonist, has recently received FDA approval for release in the United States for the treatment of hypertension. Propranolol, the prototype betaadrenoceptor blocker for clinical use, has been used in humans for a decade and a half. More recently, metoprolol and nadolol have received approval for clinical use in the United States. Atenolol was released in Europe in 1976 and has been studied widely and carefully. To most practicing physicians, a drug with the same therapeutic characteristics as others already available is not uncritically welcomed. Prescribes will seek evidence that a new agent has pharmacodynamic or pharmacokinetic...References1. SHAND D, NUCKOLLS E, and OATES J. Plasma propanolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970;11:112-20. CrossrefMedlineGoogle Scholar2. SHAND D. Individualization of propranolol therapy. Med Clin North Am. 1975;58:1063-9. CrossrefGoogle Scholar3. DREYFUSS J, BRANNICK L, VUKOVICH R, SHAW J, and WILLARD D. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977;17:300-7. CrossrefMedlineGoogle Scholar4. REEVES P, MCAINSH J, MCINTOSH D, and WINROW M. Metabolism of atenolol in man. Xenobiotica. 1978;8:313-20. CrossrefMedlineGoogle Scholar5. BROWN H, CARRUTHERS S, and JOHNSTON G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976;20:524-34. CrossrefMedlineGoogle Scholar6. MCAINSH J, HOLMES B, SMITH S, HOOD D, and WARREN D. Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980;28:302-9. CrossrefMedlineGoogle Scholar7. PETRIE J, JEFFERS T, ROBB O, SCOTT A, and WEBSTER J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. Br Med J. 1980;280:1573-4. CrossrefMedlineGoogle Scholar8. JACKSON G, SCHWARTZ J, KATES R, WINCHESTER M, and HARRISON D. Atenolol: once daily cardioselective beta blockade for angina pectoris. Circulation. 1980;61:555-60. CrossrefMedlineGoogle Scholar9. LANDS A, ARNOLD A, MCAULIFF J, LUDUENA F, and BROWN T. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967;214:597-8. CrossrefMedlineGoogle Scholar10. HARMS H. Isoproterenol antagonism of cardioselective beta adrenergic blocking agents: a comparative study of human and guinea pig cardiac and bronchial beta adrenergic receptors. J Pharmacol Exp Ther. 1976;199:329-35. MedlineGoogle Scholar11. DEACON S, KARUNANAYAKE A, and BARNETT D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes. Br Med J. 197;2:1255-7. CrossrefMedlineGoogle Scholar12. SMITH U. Effect of beta-adrenoceptor blocking agents on the reaction to hypoglycemia and the physical working capacity. Cardiovasc Rev Rep. 1981;2:563-7. Google Scholar13. MCDEVITT D. Beta-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol. 1978;5:97-9. CrossrefMedlineGoogle Scholar14. MYERS M and HOPE-GILL H. Effect of d- and dl-propranolol on glucose-stimulated insulin release. Clin Pharmcol Ther. 1979;25:303-8. CrossrefMedlineGoogle Scholar15. JEFFERS T, WEBSTER J, REID B, and PETRIE J. Atenolol and metoprolol in mild hypertension. Br Med J. 1978;2:1269. CrossrefMedlineGoogle Scholar16. PETRIE J, GALLOWAY D, WEBSTER J, SIMPSON W, and LEWIS J. Atenolol and bendrofluazide in hypertension. Br Med J. 1975;4:133-5. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ANDREW A. MCLEOD, M.B., M.R.C.P.; DAVID G. SHAND, PH.D.Affiliations: Divisions of Cardiology and Clinical Pharmacology Duke University Medical Center Durham, North Carolina PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGNA15 expression in small intestinal neuroendocrine neoplasia: Functional and signalling pathway analysesCardiovascular effects of eating, atenolol and their interaction: β1-adrenergic modulation does not play a predominant role in the genesis of postprandial effectsMedical Treatment of Renal HypertensionTherapy of Angina PectorisHemodynamic and metabolic responses to exercise after alpha1-, beta1-, and nonselective beta-adrenoceptor blockade in manDrug Prescribing in Renal Failure: Dosing Guidelines for AdultsDrugs and the KidneyCorrection: Editorial Note on Atenolol 1 February 1982Volume 96, Issue 2Page: 244-245KeywordsDrugsFood and Drug AdministrationHypertensionPharmacodynamicsPharmacokinetics ePublished: 1 December 2008 Issue Published: 1 February 1982 PDF downloadLoading ...